Reprint

Dosage Form Formulation Technologies for Improving Bioavailability

Edited by
July 2024
246 pages
  • ISBN978-3-7258-1570-8 (Hardback)
  • ISBN978-3-7258-1569-2 (PDF)
https://doi.org/10.3390/books978-3-7258-1569-2 (registering)

This book is a reprint of the Special Issue Dosage Form Formulation Technologies for Improving Bioavailability that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

This Special Issue welcomed original research papers, but was not limited to cooperative works between academia and pharmaceutical companies where reformulations or original dosage form designs were performed. Papers or reviews including the principles of Quality by Design to improve the bioavailability of drugs belonging to BCS Classes of II or IV were warmly encouraged for submission. We were looking for manuscripts that optimized innovative technology through the design of experiments as well. Non-pharma institutes or departments and their innovative research projects were also invited to contribute to this Special Issue if their novel and original results could be adapted to dosage form formulation or production.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
periodontal pocket drug delivery; poloxamer 407; hyaluronic acid; periodontitis; thermoresponsive niosome gel; hydroxytyrosol; pharmaceutical formulation; pharmacokinetics; bioavailability; DOPET; DOPAC; MOPET; HVA; human volunteers; centrifugal spinning; microfibre; amorphous solid dispersion; sucrose; poorly water-soluble drug; itraconazole; dissolution enhancement; supersaturation; tabletting; oral formulation; in vitro methods; cell culture; ex vivo methods; bioavailability; cannabidiol; cannabidiolic acid; cannabichromene; cannabis; solubility; permeability; in situ forming nanoparticles; parenteral; targeted drug delivery; design of experiment; PDLG; cholesterol; PBPK; lipid; polymer; calcium carbonate; CaCO3 particles; vaterite; metastability; recrystallization; calcite; degradation; dissolution; pH-sensitivity; resorption; biodegradation; controlled release; ayer-by-layer assembly; calcium ions; carbon dioxide bubbles; ossification; theranostics; anticancer therapy; antimicrobial therapy; US imaging; cavitation; buffering; fast-dissolving film; rosuvastatin; pharmacokinetics; hyperlipidemia; design of experiment approach; oral formulation; lipid-based formulations; poorly water-soluble drug; bioavailability enhancement; anticancer; protein kinase CK2; CK2 inhibitor DMAT; alginate microbeads; Transcutol® HP; polyvinylpyrrolidone; BGP-15; Box–Behnken design of experiment; penetration enhancers; bioavailability; transdermal patches; PVA; PVP; in vitro permeation; porcine skin; microbead; oral bioavailability; absorption enhancement; Labrasol ALF; Labrafil M 2125 CS; Caco-2 cells